Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa: a modelling study
Open Access
- 24 June 2025
- journal article
- Published by Elsevier in The Lancet HIV
- Vol. 12 (8) , e578-e586
Abstract
No abstract availableKeywords
Funding Information
- Gates Foundation
This publication has 23 references indexed in Scilit:
- Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trialThe Lancet HIV, 2024
- Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment ModificationClinical Infectious Diseases, 2024
- HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysisThe Lancet HIV, 2023
- Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort studyThe Lancet HIV, 2022
- Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trialThe Lancet HIV, 2022
- Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIVNew England Journal of Medicine, 2021
- Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE TrialClinical Infectious Diseases, 2021
- OLA-Simple: A software-guided HIV-1 drug resistance test for low-resource laboratoriesEBioMedicine, 2019
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIVNew England Journal of Medicine, 2019
- Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling studyThe Lancet HIV, 2019